Keywords: H1N1, swine flu, Biosante, BioVant
BioSante’s BioVant gives 100% protection from H1N1 challenge
Article | 18 August 2009
Illinois, USA-based BioSante Pharmaceuticals has presented H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence showing that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
